Our Science

Abstracts and Publications

Select A2 Biotherapeutics™ Scientific Publications

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas

Kirtane K, St. John M, Fuentes-Bayne H, et al. Genomic Immune Evasion: December 2022.

VIEW ARTICLE A2 Bio External Link icon

HLA-A∗02-gated Safety Switch for Cancer Therapy Has Exquisite Specificity for Its Allelic Target Antigen

Mock JY, Winters A, Riley TP, et al. Molecular Therapy: October 2022.

VIEW ARTICLE A2 Bio External Link icon

The Tmod Cellular Logic Gate As a Solution for Tumor-selective Immunotherapy

DiAndreth B, Hamburger A, Xu H, et al. Clinical Immunology: August 2022.

VIEW ARTICLE A2 Bio External Link icon

The End of an Era of Cancer Drug Discovery: Life Without New Drug Targets

Mardiros A, Kamb A. Immuno-oncology Insights: April 2022.

VIEW ARTICLE A2 Bio External Link icon

Robust In Vitro Pharmacology of Tmod, A Synthetic Dual-Signal Integrator for Cancer Cell Therapy

Manry D, Bolanos K, DiAndreth B, et al. Frontiers in Immunology: March 2022.

VIEW ARTICLE A2 Bio External Link icon

A Carcinoembryonic Antigen-specific Cell Therapy Selectively Targets Tumor Cells with HLA Loss of Heterozygosity in Vitro and In Vivo

Sandberg M, Wang X, Martin A, et al. Science Translational Medicine: March 2022.

VIEW ARTICLE A2 Bio External Link icon

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity

Tokatlian T, Asuelime G, Naradikian M, et al. Cancer Research Communications: January 2022.

VIEW ARTICLE A2 Bio External Link icon

A Rational Approach to Assess Off-Target Reactivity of a Dual-Signal Integrator for T Cell Therapy

Wang X, Wong LM, McElvain M, et al. Toxicology and Applied Pharmacology: January 2022.

VIEW ARTICLE A2 Bio External Link icon

Mesothelin-Specific CAR-T Cell Therapy that Incorporates an HLA-Gated Safety Mechanism Selectively Kills Tumor Cells

Tokatlian T, Asuelime G, Mock JY, et al. Journal of ImmunoTherapy for Cancer: January 2022.

VIEW ARTICLE A2 Bio External Link icon

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang X, Sandberg M, Martin A, et al. Journal of Immunotherapy: October 2021.

VIEW ABSTRACT A2 Bio External Link icon

Extensive Functional Comparisons Between Chimeric Antigen Receptors and T-cell Receptors Highlight Fundamental Similarities

Wang X, Martin A, Negri K, et al. Molecular Immunology:  October 2021.

VIEW ABSTRACT A2 Bio External Link icon

Design of TCR Structural Variants That Retain or Invert the Normal Activation Signal

Mock JY, Oh J, Yi J, et al. ImmunoHorizons: May 1, 2021.

VIEW ABSTRACT A2 Bio External Link icon

Re-examination of MAGE-A3 as a T-cell Therapeutic Target

Martin A, Wang X, Sandberg M, et al. Journal of Immunotherapy: April 2021.

VIEW ARTICLE A2 Bio External Link icon

HLA-A*02:01-directed Chimeric Antigen Receptor/Forkhead Box P3-engineered CD4+ T cells Adopt a Regulatory Phenotype and Suppress Established Graft-versus-host Disease

Martin A, Daris M, Johnston J, et al. Cytotherapy: February 2021.

VIEW ARTICLE A2 Bio External Link icon

Engineered T-cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Molecular Immunology: December 2020.

VIEW ARTICLE A2 Bio External Link icon

A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro

Huang GL, Nampe DP, Yi J, et al. PLoS ONE: November 2020.

VIEW ARTICLE A2 Bio External Link icon

Structure-function Relationships of Chimeric Antigen Receptors in Acute T-cell Responses to Antigen

Xu H, Hamburger A, Mock JY, et al. Molecular Immunology: October 2020.

VIEW ARTICLE A2 Bio External Link icon

Cancer T-cell Therapy: Building the Foundation for a Cure

Kamb A, Go W. F1000 Research: November 2020.

VIEW ARTICLE A2 Bio External Link icon

Single variable domains from the T cell receptor β chain function as mono- and bifunctional CARs and TCRs

Oh J, Warshaviak D, Mkrtichyan M, et al. Scientific Report: November 2019.

VIEW ARTICLE A2 Bio External Link icon

IASLC Poster 2023 February

BASECAMP-1: Leveraging Human Leukocyte Antigen A (HLA-A) Loss of Heterozygosity (LOH) in Solid Tumors to Identify Patients for Carcinoembryonic Antigen (CEA) and Mesothelin (MSLN) Logic-Gated Tmod Chimeric Antigen Receptor (CAR) T-Cell Therapy

Smith CJ, Lau S, Garon E, et al. Poster presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 Targeted Therapies of Lung Cancer Meeting. February 2023.

VIEW POSTER A2 Bio External Link icon

BASECAMP-1: Leveraging HLA-A Loss of Heterozygosity in Solid Tumors by NGS to Identify Patients with Relapsed Solid Tumors for Future CEA and MSLN Logic-gated Tmod CAR T-cell Therapy.

Simeone DM, Morelli MP, Hecht JR, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER A2 Bio External Link icon

An NGS Assay to Identify HLA-A Loss of Heterozygosity for Future CEA and MSLN Logic-gated CAR-T Solid Tumor Protocols Designed for Reduced On-target, Off-tumor Toxicity

Kopetz S, Morelli MP, Molina J, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER A2 Bio External Link icon

A2B530, An Autologous CEA-directed Tmod T-cell therapy with An Inhibitory Receptor Gated by HLA-A*02 to Target Colorectal, Pancreatic, and Lung Cancer

Hecht, JR Sandberg ML, Wang X, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER A2 Bio External Link icon

A2B694, An Autologous Logic-gated Cell Therapy Targeting Mesothelin

Molina J, Tokatlian T, Wang J, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2022.

VIEW POSTER A2 Bio External Link icon

A2 Bio A powerful precise Poster Thumbnail

A Powerful, Precise Targeting System Controlled by Tumor Deletions Transforms CEA and MSLN CAR-T Cells Into Tumor-Selective Agents

Hamburger A, Xu H, Ando Y, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER A2 Bio External Link icon

A2 Bio Basecamp-1 Poster Thumbnail

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J, Go W, Kopetz S, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER A2 Bio External Link icon

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

Warshaviak D, Nampe D, Wang X, et al. Poster presentation at The Essential Protein Engineering & Cell Therapy Summit Virtual. August 2020.

VIEW POSTER A2 Bio External Link icon

Breanna DiAndreth, PhD, on Improving Selective Targeting of Tumor Cells

DiAndreth A. Interview conducted at Onco Cell Therapy Summit (OCTS) USA 2022. June 2022.

VIEW INTERVIEW A2 Bio External Link icon

The Future of Logic-gated Cell Therapy

Go W. Interview conducted at the 4th International Workshop on CAR-T (iwCAR-T 2022). April 2022.

VIEW INTERVIEW A2 Bio External Link icon

Julian Molina genetherapylive

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW A2 Bio External Link icon

Julian Molina genetherapylive

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW A2 Bio External Link icon

TmodTM T cell Therapy Platform By Alexandar Kamb Thumbnail 2021NOVEMBER24 V2 F

Tmod™ T cell Therapy Platform Overview

Kamb, A. Interviews conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW A2 Bio External Link icon

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J. Oral poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW PRESENTATION A2 Bio External Link icon

Managing Clinical Safety and Toxicity for Improved Patient Outcomes

Go W. Oral presentation at CAR-TCR Summit 2021. August 2021.   

VIEW PRESENTATION A2 Bio External Link icon

Optimizing Efficiency in Trial Sponsor and Clinician Relationships

Geiger B, Matthews A, Melvin P, et al. Panel discussion at CAR-TCR Summit 2021. August 2021.   

VIEW PRESENTATION A2 Bio External Link icon

Next-generation Logic-gated Cell Therapy

Go W. Oral presentation at the International Workshop on CAR-T 2021. April 2021.

VIEW PRESENTATION A2 Bio External Link icon

Engineered T Cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Oral presentation at 3rd Cell Therapies and Immunotherapy Conference. October 2020.

VIEW PRESENTATION A2 Bio External Link icon

Explore Our Pipeline

A2 BIOTHERAPEUTICS, Reg. U.S. Pat. & Tm. Off.